<DOC>
	<DOCNO>NCT01474798</DOCNO>
	<brief_summary>This 91-day phase II , open label trial true human monoclonal antibody RA-18C3 subject moderate severe acne vulgaris . Ten ( 10 ) subject receive RA-18C3 via subcutaneous injection . Subjects receive injection Days 0 , 21 , 42 total 3 injection . Study drug administer close observation facility equip handle medical emergency . Subjects discharge facility least 1 hour follow injection 1 hour vital sign stabilize . Safety assess pre- post-treatment serial measurement vital sign , clinical laboratory assessment , record adverse clinical event .</brief_summary>
	<brief_title>Phase II Trial RA-18C3 Subjects With Moderate Severe Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Age : ≥ 18 2 . Moderate moderately severe inflammatory acne vulgaris : Investigator 's Global Assessment grade ≥ 3 , ≥ 15 inflammatory lesion ( 6 nodule ) , ≥ 15 noninflammatory lesion 3 . Four week washout period topical oral antibiotic treatment 4 . Four week washout period topical retinoids 5 . Negative pregnancy test screen specify time point throughout trial . For subject reproductive potential , willingness utilize contraception study include 3 month study completion . Sexually active men must use accepted method contraception study include 3 month study completion . 6 . Subjects weigh ≥ 27 kg 7 . Signed date Institutional Review Board ( IRB ) approve informed consent protocolspecific screening procedure perform 1 . A diagnosis Acne conglobata , acne fulminans , secondary acne , severe nodulocystic acne require treatment isotretinoin , dermatologic condition require interfere phototherapy , topical , systemic treatment . 2 . Treatment biologicals investigational agent within last 4 week ( 5 halflives , whichever long ) . 3 . Men facial hair would interfere assessment 4 . History uncontrolled diabetes , unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , recent stroke ( within 3 month ) , ongoing congestive heart failure , condition , opinion investigator , would put subject risk participation protocol . 5 . Hemoglobin &lt; 10.0 g/dL , WBC &lt; 3.0 x 103/mm3 , platelet count &lt; 125 x 103/mm3 , creatinine &gt; 1.5mg/dL , AST/ALT &gt; 2 x ULN , alkaline phosphatase &gt; 2 x ULN 6 . Known HIV antibody , hepatitis B surface antigen and/or hepatitis C antibody . 7 . History malignancy within 5 year prior study entry carcinoma situ cervix , adequately treat , nonmetastatic squamous basal cell carcinoma skin . 8 . History severe allergic anaphylactic reaction humanize murine monoclonal antibody . 9 . History tuberculosis ( latent active ) positive Interferongamma release assay ( IGRA ) 10 . Infectious disease : CRP &gt; 30 mg/L , fever , infection require treatment antibiotic within 3 week prior Screening 11 . Immunodeficiency 12 . Female subject pregnant , plan become pregnant course study , breastfeed 13 . Receipt live ( attenuate ) vaccine within 1 month prior Screening 14 . Major surgery within 28 day prior Day 0 15 . Participation investigational drug device trial within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Acne Vulgaris</keyword>
</DOC>